HC Wainwright Reaffirms Buy Rating for Mural Oncology HC Wainwright analysts reiterated a Buy rating for Mural Oncology, setting a $18 price target, representing significant upside potential. The company’s lead drug candidates, including nemvaleukin alfa, are expected to achieve critical clinical milestones in 2025, potentially reshaping its valuation profile.3